Telix Files 2025 Corporate Governance Statement and Appendix 4G with ASX

Telix Pharmaceuticals ( (AU:TLX) ) has provided an update.

Telix Pharmaceuticals has lodged its latest corporate governance statement with the ASX for the financial year ended 31 December 2025, confirming that the document is current as of 20 February 2026 and available on the company’s investor relations website. The accompanying Appendix 4G outlines how Telix complies with the ASX Corporate Governance Council’s principles, including board charters, director appointment processes and company secretary accountability, reinforcing its adherence to best-practice governance and disclosure requirements for shareholders.

The filing confirms that Telix has followed key governance recommendations such as written agreements for directors and senior executives and clear delineation of board and management responsibilities. By mapping its disclosures against ASX rules and council recommendations, Telix provides investors with greater transparency on its oversight structures, risk management and decision-making processes, supporting confidence in the company’s governance framework.

The most recent analyst rating on (AU:TLX) stock is a Buy with a A$34.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.

More about Telix Pharmaceuticals

Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on developing and commercialising radiopharmaceuticals for the diagnosis and treatment of cancer and other serious diseases. The company targets global oncology markets, aligning its operations with Australian Securities Exchange governance and reporting standards as part of its listed-entity obligations.

Average Trading Volume: 2,324,604

Technical Sentiment Signal: Sell

Current Market Cap: A$2.99B

For detailed information about TLX stock, go to TipRanks’ Stock Analysis page.